Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols NR3C1 and ZBTB9	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 zinc finger and BTB domain containing 9	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel Novel	Symbols NR3C1 and TNS4	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 tensin 4	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 MET interacts with TNS proteins	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel Novel	Symbols KPNA2 and GMCL1	Name 1 karyopherin subunit alpha 2	Name2 germ cell-less 1, spermatogenesis associated	Pathway 1 CaMK IV-mediated phosphorylation of CREB ISG15 antiviral mechanism NS1 Mediated Effects on Host Pathways CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde Sensing of DNA Double Strand Breaks Estrogen-dependent gene expression SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DAXX and RASSF1	Name 1 death domain associated protein	Name2 Ras association domain family member 1	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DAXX and DNMT1	Name 1 death domain associated protein	Name2 DNA methyltransferase 1	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2 PRC2 methylates histones and DNA NoRC negatively regulates rRNA expression SUMOylation of DNA methylation proteins DNA methylation STAT3 nuclear events downstream of ALK signaling Defective pyroptosis Nuclear events stimulated by ALK signaling in cancer	Drugs 1	Drugs 2 Procaine Azacitidine Procainamide Flucytosine Decitabine Palifosfamide Epigallocatechin gallate	Diseases 1	Diseases 2
Novel Novel	Symbols DAXX and SPOP	Name 1 death domain associated protein	Name2 speckle type BTB/POZ protein	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2 Hedgehog 'on' state SPOP-mediated proteasomal degradation of PD-L1(CD274)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DAXX and CDCA7L	Name 1 death domain associated protein	Name2 cell division cycle associated 7 like	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRIK2 and PRKAA1	Name 1 glutamate ionotropic receptor kainate type subunit 2	Name2 protein kinase AMP-activated catalytic subunit alpha 1	Pathway 1 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Pathway 2 Macroautophagy Energy dependent regulation of mTOR by LKB1-AMPK TP53 Regulates Metabolic Genes Regulation of TP53 Activity through Phosphorylation Activation of AMPK downstream of NMDARs AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)	Drugs 1 Glutamic acid Butabarbital Butalbital Topiramate Talbutal Pentobarbital Secobarbital Metharbital Thiopental Primidone Methylphenobarbital Phenobarbital Amobarbital Aprobarbital Butobarbital Heptabarbital Hexobarbital Barbital Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione Domoic Acid Quisqualic acid 2s,4r-4-Methylglutamate	Drugs 2 Adenosine phosphate Adenosine phosphate ATP Phenformin Acetylsalicylic acid Fostamatinib Fostamatinib	Diseases 1 Nonsyndromic autosomal recessive mental retardation (NS-ARMR)	Diseases 2
Novel Novel	Symbols GRIK1 and PTPRD	Name 1 glutamate ionotropic receptor kainate type subunit 1	Name2 protein tyrosine phosphatase receptor type D	Pathway 1 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Pathway 2 Receptor-type tyrosine-protein phosphatases Synaptic adhesion-like molecules	Drugs 1 Glutamic acid Butabarbital Topiramate Tezampanel	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRIK1 and LDB2	Name 1 glutamate ionotropic receptor kainate type subunit 1	Name2 LIM domain binding 2	Pathway 1 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Pathway 2	Drugs 1 Glutamic acid Butabarbital Topiramate Tezampanel	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GNAO1 and HRH4	Name 1 G protein subunit alpha o1	Name2 histamine receptor H4	Pathway 1 Ca2+ pathway Ca2+ pathway	Pathway 2 Histamine receptors G alpha (i) signalling events	Drugs 1	Drugs 2 Amitriptyline Clozapine Loxapine Chlorpromazine Amoxapine Doxepin Aripiprazole Pheniramine REV131 Histamine Mianserin	Diseases 1	Diseases 2
Novel Novel	Symbols GNAI2 and GPSM3	Name 1 G protein subunit alpha i2	Name2 G protein signaling modulator 3	Pathway 1 Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway ADP signalling through P2Y purinoceptor 12 Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Regulation of insulin secretion Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production	Pathway 2 G alpha (i) signalling events	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma	Diseases 2
Novel Novel	Symbols GNAI2 and PCP2	Name 1 G protein subunit alpha i2	Name2 Purkinje cell protein 2	Pathway 1 Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway ADP signalling through P2Y purinoceptor 12 Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Regulation of insulin secretion Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production	Pathway 2 G alpha (i) signalling events	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma	Diseases 2
Novel Novel	Symbols GNAI3 and PRKAR2B	Name 1 G protein subunit alpha i3	Name2 protein kinase cAMP-dependent type II regulatory subunit beta	Pathway 1 Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway ADP signalling through P2Y purinoceptor 12 G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production	Pathway 2 PKA activation PKA activation in glucagon signalling DARPP-32 events Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins CREB1 phosphorylation through the activation of Adenylate Cyclase Hedgehog 'off' state Anchoring of the basal body to the plasma membrane AURKA Activation by TPX2 GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis Factors involved in megakaryocyte development and platelet production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1	Drugs 2 Cyclic adenosine monophosphate	Diseases 1	Diseases 2
Novel Novel	Symbols HSF2 and DERA	Name 1 heat shock transcription factor 2	Name2 deoxyribose-phosphate aldolase	Pathway 1	Pathway 2 Neutrophil degranulation Pentose phosphate pathway	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols C1QBP and GAB1	Name 1 complement C1q binding protein	Name2 GRB2 associated binding protein 1	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2 PI3K Cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PIP3 activates AKT signaling GAB1 signalosome PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling MET activates PTPN11 MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols C1QBP and MMP14	Name 1 complement C1q binding protein	Name2 matrix metallopeptidase 14	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2 Collagen degradation Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases TGFBR3 PTM regulation High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1 Hyaluronic acid Copper	Drugs 2 Marimastat	Diseases 1	Diseases 2
Novel Novel	Symbols C1QBP and MIR1-1	Name 1 complement C1q binding protein	Name2 microRNA 1-1	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols C1QBP and MIR29A	Name 1 complement C1q binding protein	Name2 microRNA 29a	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols C1QBP and MIR29B1	Name 1 complement C1q binding protein	Name2 microRNA 29b-1	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NR3C1 and ZBTB9	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 zinc finger and BTB domain containing 9	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel	Symbols NR3C1 and TNS4	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 tensin 4	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 MET interacts with TNS proteins	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel	Symbols KPNA2 and GMCL1	Name 1 karyopherin subunit alpha 2	Name2 germ cell-less 1, spermatogenesis associated	Pathway 1 CaMK IV-mediated phosphorylation of CREB ISG15 antiviral mechanism NS1 Mediated Effects on Host Pathways CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde Sensing of DNA Double Strand Breaks Estrogen-dependent gene expression SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DAXX and RASSF1	Name 1 death domain associated protein	Name2 Ras association domain family member 1	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DAXX and DNMT1	Name 1 death domain associated protein	Name2 DNA methyltransferase 1	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2 PRC2 methylates histones and DNA NoRC negatively regulates rRNA expression SUMOylation of DNA methylation proteins DNA methylation STAT3 nuclear events downstream of ALK signaling Defective pyroptosis Nuclear events stimulated by ALK signaling in cancer	Drugs 1	Drugs 2 Procaine Azacitidine Procainamide Flucytosine Decitabine Palifosfamide Epigallocatechin gallate	Diseases 1	Diseases 2
Novel	Symbols DAXX and SPOP	Name 1 death domain associated protein	Name2 speckle type BTB/POZ protein	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2 Hedgehog 'on' state SPOP-mediated proteasomal degradation of PD-L1(CD274)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DAXX and CDCA7L	Name 1 death domain associated protein	Name2 cell division cycle associated 7 like	Pathway 1 SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRIK2 and PRKAA1	Name 1 glutamate ionotropic receptor kainate type subunit 2	Name2 protein kinase AMP-activated catalytic subunit alpha 1	Pathway 1 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Pathway 2 Macroautophagy Energy dependent regulation of mTOR by LKB1-AMPK TP53 Regulates Metabolic Genes Regulation of TP53 Activity through Phosphorylation Activation of AMPK downstream of NMDARs AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)	Drugs 1 Glutamic acid Butabarbital Butalbital Topiramate Talbutal Pentobarbital Secobarbital Metharbital Thiopental Primidone Methylphenobarbital Phenobarbital Amobarbital Aprobarbital Butobarbital Heptabarbital Hexobarbital Barbital Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione Domoic Acid Quisqualic acid 2s,4r-4-Methylglutamate	Drugs 2 Adenosine phosphate Adenosine phosphate ATP Phenformin Acetylsalicylic acid Fostamatinib Fostamatinib	Diseases 1 Nonsyndromic autosomal recessive mental retardation (NS-ARMR)	Diseases 2
Novel	Symbols GRIK1 and PTPRD	Name 1 glutamate ionotropic receptor kainate type subunit 1	Name2 protein tyrosine phosphatase receptor type D	Pathway 1 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Pathway 2 Receptor-type tyrosine-protein phosphatases Synaptic adhesion-like molecules	Drugs 1 Glutamic acid Butabarbital Topiramate Tezampanel	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRIK1 and LDB2	Name 1 glutamate ionotropic receptor kainate type subunit 1	Name2 LIM domain binding 2	Pathway 1 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Pathway 2	Drugs 1 Glutamic acid Butabarbital Topiramate Tezampanel	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GNAO1 and HRH4	Name 1 G protein subunit alpha o1	Name2 histamine receptor H4	Pathway 1 Ca2+ pathway Ca2+ pathway	Pathway 2 Histamine receptors G alpha (i) signalling events	Drugs 1	Drugs 2 Amitriptyline Clozapine Loxapine Chlorpromazine Amoxapine Doxepin Aripiprazole Pheniramine REV131 Histamine Mianserin	Diseases 1	Diseases 2
Novel	Symbols GNAI2 and GPSM3	Name 1 G protein subunit alpha i2	Name2 G protein signaling modulator 3	Pathway 1 Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway ADP signalling through P2Y purinoceptor 12 Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Regulation of insulin secretion Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production	Pathway 2 G alpha (i) signalling events	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma	Diseases 2
Novel	Symbols GNAI2 and PCP2	Name 1 G protein subunit alpha i2	Name2 Purkinje cell protein 2	Pathway 1 Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway ADP signalling through P2Y purinoceptor 12 Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Regulation of insulin secretion Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production	Pathway 2 G alpha (i) signalling events	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma	Diseases 2
Novel	Symbols GNAI3 and PRKAR2B	Name 1 G protein subunit alpha i3	Name2 protein kinase cAMP-dependent type II regulatory subunit beta	Pathway 1 Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway ADP signalling through P2Y purinoceptor 12 G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production	Pathway 2 PKA activation PKA activation in glucagon signalling DARPP-32 events Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins CREB1 phosphorylation through the activation of Adenylate Cyclase Hedgehog 'off' state Anchoring of the basal body to the plasma membrane AURKA Activation by TPX2 GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis Factors involved in megakaryocyte development and platelet production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1	Drugs 2 Cyclic adenosine monophosphate	Diseases 1	Diseases 2
Novel	Symbols HSF2 and DERA	Name 1 heat shock transcription factor 2	Name2 deoxyribose-phosphate aldolase	Pathway 1	Pathway 2 Neutrophil degranulation Pentose phosphate pathway	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols C1QBP and GAB1	Name 1 complement C1q binding protein	Name2 GRB2 associated binding protein 1	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2 PI3K Cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PIP3 activates AKT signaling GAB1 signalosome PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling MET activates PTPN11 MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols C1QBP and MMP14	Name 1 complement C1q binding protein	Name2 matrix metallopeptidase 14	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2 Collagen degradation Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases TGFBR3 PTM regulation High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1 Hyaluronic acid Copper	Drugs 2 Marimastat	Diseases 1	Diseases 2
Novel	Symbols C1QBP and MIR1-1	Name 1 complement C1q binding protein	Name2 microRNA 1-1	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols C1QBP and MIR29A	Name 1 complement C1q binding protein	Name2 microRNA 29a	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols C1QBP and MIR29B1	Name 1 complement C1q binding protein	Name2 microRNA 29b-1	Pathway 1 Apoptotic factor-mediated response Intrinsic Pathway of Fibrin Clot Formation RHOA GTPase cycle RHOC GTPase cycle Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	Pathway 2	Drugs 1 Hyaluronic acid Copper	Drugs 2	Diseases 1	Diseases 2

Page 35 out of 98 pages

Search Results : Cancer